Biochemical efficacy of vitamin D in ameliorating endocrine and metabolic disorders in diabetic rats

Pharmaceutical Biology

Volumn 52, Issue 5, 2014, Pages 591-596

  Sadek, Kadry M ^a   Shaheen, Hazem ^a  

^a DAMANHOUR UNIVERSITY   (Egypt)

Author keywords

Diabetes mellitus; Insulin resistance; Interleukin 6; Ketoacidosis

Indexed keywords

BETA HYDROXYL BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 6; PLACEBO; STREPTOZOCIN; UNCLASSIFIED DRUG; VIDROP; 3 HYDROXYBUTYRIC ACID; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC KETOACIDOSIS; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; RAT; RECOMMENDED DRUG DOSE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREATMENT DURATION; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENDOCRINE SYSTEM; IMMUNOLOGY; METABOLISM; SECRETION (PROCESS); WISTAR RAT;

3-HYDROXYBUTYRIC ACID; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOCRINE SYSTEM; FATTY ACIDS, NONESTERIFIED; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTERLEUKIN-6; MALE; RATS, WISTAR; STREPTOZOCIN; VITAMIN D;

EID: 84898423899     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2013.854812     Document Type: Article

References (46)

1. Baeke F, Van Etten E, Gysemans C, et al. (2008). Vitamin D signaling in immune-mediated disorders: Evolving insights and therapeutic opportunities. Mol Aspects Med 2:376-87.
2. Bazan JF. (1990). For the quantitative determination of interleukin-6 (IL-6) concentrations in serum, plasma, cell culture supernatant, and other biological fluids. Immunol Today 11:350-7.
3. Bikle D. (2009). Nonclassic actions of vitamin D. J Clin Endocrinol Metab 94:26-34.
4. Boucher BJ. (2011). Vitamin D insufficiency and diabetes risks. Curr Drug Targets 12:61-87.
5. Bouillon R, Carmeliet G, Verlinden L, et al. (2008). Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocrine Rev 29:726-76.
6. Bourlon PM, Billaudel B, Faure-Dussert A. (1999). Influence of vitamin D3 deficiency and 1, 25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol 160:87-95.
7. Brannon PM, Yetley EA, Bailey RL, Picciano MF. (2008). Overview of the conference "Vitamin D and Health in the 21st Century: An Update". Am J Clin Nutr 88:483-90.
8. Chiu KC, Chu A, Go VLW, Saad MF. (2004). Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79:820-5.
9. Daga RA, Laway BA, Shah ZA, et al. (2012). High prevalence of vitamin D deficiency among newly diagnosed youth-onset diabetes mellitus in north India. Arq Bras Endocrinol Metabol 56:423-8.
10. Danescu LG, Levy S, Levy J. (2009). Vitamin D and diabetes mellitus. Endocrinology 35:11-17.
11. de Souza Santos R, Vianna LM. (2005). Effect of cholecalciferol supplementation on blood glucose in an experimental model of type 2 diabetes mellitus in spontaneously hypertensive rats and Wistar rats. Clin Chim Acta 358:146-50.
12. Duncombe WG. (1964). The calorimetric micro determination of non-esterified fatty acids and betahydroxy butyric acid in plasma. Chem Acta 9:122-5.
13. Dunlop TW, Vaisanen S, Frank C, et al. (2005). The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha, 25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol 349:248-60.
14. Forouhi NG, Luan J, Cooper A, et al. (2008). Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 57:2619-25.
15. Fujita T, Palmieri GM. (2000). Calcium paradox disease: Calcium deficiency prompting secondary hyperparathyroidism and cellular calcium overload. J Bone Miner Metab 18:109-25.
16. Gindler M, King JD. (1972). Rapid colourimetric determination of calcium in biological fluids with methylthymol blue. Am J Clin Path 58:376-82.
17. Hypponen E, Laara E, Reunanen A, et al. (2001). Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 358:1500-3.
18. Isaia G, Giorgino R, Adami S. (2001). High prevalence of hypovitami-nosis D in female type 2 diabetic population. Diabetes Care 24: 1496-507.
19. Jeppsson JO, Kobold U, Barr J, Finke A. (2002). Approved IFCC reference method for the measurement of HbA1c in blood. Clin Chem Lab Med 40:785-9.
20. Jódar-Gimeno E, Muñoz-Torres M. (2012). Vitamin D hormone system and diabetes mellitus: Lessons from selective vitamin D receptor activators: Selective activators of vitamin D receptor and diabetes mellitus. Endocrinol Nutr 2:109-17.
21. Kayaniyil S, Retnakaran R, Harris SB, et al. (2011). Prospective associations of vitamin D with b-cell function and glycemia. Diabetes 60:2948-53.
22. Luo C, Wong J, Brown M, et al. (2009). Hypovitaminosis D in Chinese type 2 diabetes: Lack of impact on clinical metabolic status and biomarkers of cellular inflammation. Diabet Vas Dis Res 6:194-9.
23. Maestro B, Molero S, Bajo S, et al. (2002). Transcriptional activation of the human insulin receptor gene by 1, 25-dihydroxyvitamin D(3). Cell Biochem Funct 20:227-32.
24. Mathieu C, Gysemans C, Giulietti A, Bouillon R. (2005). Vitamin D and diabetes. Diabetologia 48:1247-57.
25. Matsuda M, DeFronzo RA. (1999). Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-70.
26. Matthews DR, Hosker JP, Rudenski AS, et al. (1985). Homeostasis model assessment insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28:412-19.
27. Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. (2011a). Effects of vitamin D and calcium supplementation on pancreatic b-cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: The Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr 29:1-9.
28. Mitri J, Muraru MD, Pittas AG. (2011b). Vitamin D and type 2 diabetes: A systematic review. Eur J Clin Nutr 65:1005-1015.
29. Mohr SB, Garland CF, Gorham ED, Garland FC. (2008). The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 51: 1391-8.
30. Nikooyeh B, Neyestani TR, Farvid M, et al. (2011). Daily consumption of vitamin D-or vitamin D calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: A randomized clinical trial. Am J Clin Nutr 93:764-71.
31. Norman AW. (2008). From vitamin D to hormone D: Fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88:491-9.
32. Orwoll E, Riddle M, Prince M. (1994). Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr 59:1083-7.
33. Overbergh L, Decallonne B, Waer M, et al. (2000). 1a, 25-Dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes 49:1301-7.
34. Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D. (2008). Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 10:185-97.
35. Paolisso G, Rizzo MR, Mazziotti G, et al. (1998). Advancing age and insulin resistance: Role of plasma tumor necrosis factor-a. Am J Physiol 275:294-9.
36. Peterlik M, Cross HS. (2005). Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 35:290-304.
37. Pittas AG, Dawson-Hughes B, Li T, et al. (2006). Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 29: 650-6.
38. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. (2007). The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in non-diabetic adults. Diabetes Care 30: 980-6.
39. Riachy R, Vandewalle B, Belaich S, et al. (2001). Beneficial effect of 1, 25 dihydroxyvitamin D3 on cytokine-treated human pancreatic islets. J Endocrinol 169:161-8.
40. Tai K, Need AG, Horowitz M, Chapman IM. (2008). Glucose tolerance and vitamin D: Effects of treating vitamin D deficiency. Diabetes Care 24:950-6.
41. Takiishi T, Gysemans C, Bouillon R, Mathieu C. (2010). Vitamin D and diabetes. Endocrinol Metab Clin North Am 39:419-46.
42. Taylor AV, Wise PH. (1998). Vitamin D replacement in Asians with diabetes may increase insulin resistance. Postgrad Med J 74: 365-6.
43. Trinder P. (1969). Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6: 24-5.
44. Wareham NJ, Phillips DI, Byrne CD, Hales CN. (1995). The 30-minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med 12:931-42.
45. Wilson MA, Miles LSM. (1977). Radioimmunoassay of insulin. In: Abraham GE, ed. Handbook of Radioimmunoassay. New York: Marcel Dekker, 257-71.
46. Wu T, Willett WC, Giovannucci E. (2009). Plasma C-peptide is inversely associated with calcium intake in women and with plasma 25-hydroxy vitamin D in men. J Nutr 139:547-54.